Profiling of three H3F3A-mutated and denosumab-treated giant cell tumors of bone points to diverging pathways during progression and malignant transformation

Giant cell tumor of bone (GCTB) is a locally aggressive lesion of intermediate malignancy. Malignant transformation of GCTB is a rare event. In 2013, the humanized monoclonal antibody against receptor activator of nuclear factor-κb-Ligand (RANKL) denosumab was approved for treatment of advanced GCTB...

Descripción completa

Detalles Bibliográficos
Autores principales: Hasenfratz, Marc, Mellert, Kevin, Marienfeld, Ralf, von Baer, Alexandra, Schultheiss, Markus, Roitman, P. D., Aponte-Tinao, L. A., Lehner, Burkhard, Möller, Peter, Mechtersheimer, Gunhild, Barth, Thomas F. E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7952552/
https://www.ncbi.nlm.nih.gov/pubmed/33707617
http://dx.doi.org/10.1038/s41598-021-85319-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7952552/
https://www.ncbi.nlm.nih.gov/pubmed/33707617
http://dx.doi.org/10.1038/s41598-021-85319-x

Ejemplares similares